Coagulation Mold With Particle-Size Control for Homogeneous Blood Masses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing coagulated blood masses for medical treatments face challenges in achieving homogeneous clot formation and stability, particularly due to uneven distribution of coagulation initiators, leading to inconsistent treatment efficacy.
Innovation Solution
The method involves controlling the particle size distribution of coagulation initiators like calcium gluconate and kaolin powder, ensuring they remain suspended in whole blood for an optimal duration, and adjusting the amount mixed to achieve a stable and homogeneous coagulated blood mass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If coagulation initiators are added to whole blood, then coagulation is initiated, but the distribution becomes uneven leading to non-homogeneous clot formation
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution of coagulation initiators (specifically targeting a D50 between 50-200 micrometers for calcium gluconate and D50 less than 20 micrometers for kaolin). This parameter modification ensures the particles remain suspended in whole blood for the optimal duration, preventing premature settling and achieving uniform distribution throughout the blood volume, thereby producing homogeneous coagulated blood mass with consistent texture throughout.
2Stability of the object's composition
If larger particles of coagulation initiator are used, then suspension is improved, but particles sink too quickly reducing homogeneity
Solution Approach 1:
The patent resolves this contradiction by precisely controlling the particle size parameters of coagulation initiators. By setting the D50 particle size between 50-200 micrometers for calcium gluconate and less than 20 micrometers for kaolin, the invention achieves the optimal balance where particles remain suspended long enough to distribute uniformly throughout the blood, yet are not so large as to settle prematurely. This parameter optimization ensures both adequate suspension stability and homogeneous clot formation.
3Productivity
If coagulation initiators dissolve rapidly, then coagulation is accelerated, but homogeneity of the clot is reduced
Solution Approach 1:
The patent addresses this contradiction through parameter changes in particle size distribution. By optimizing the D50 to specific ranges (50-200 micrometers for calcium gluconate, less than 20 micrometers for kaolin), the invention achieves a balanced dissolution rate. The particles are fine enough to dissolve and release coagulation factors at a controlled pace, ensuring rapid yet uniform coagulation throughout the blood mass, rather than rapid localized coagulation that would create heterogeneous texture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a coagulated blood mass with uniform texture and improved stability, suitable for treating various bodily lesions and injuries by ensuring consistent coagulation across the entire mass.
Implementation Method 1
The whole blood is mixed with coagulation initiators, i.e. coagulation agents or anti-anti coagulation agents, in a specific amount and having specific characteristics in order to obtain the coagulated blood mass
Implementation Method 2
Another parameter to yield the desired coagulated blood mass of the present invention is the selected amount of material of coagulation initiator to be mixed with the whole blood. By controlling theses parameters, an optimal coagulated blood mass is obtained
Data Source
AI summary
The present disclosure provides a method, a coagulation mold and a kit for preparing a coagulated blood mass having a desired shape and volume. The coagulated blood mass is prepared from whole blood being withdrawn from a subject. The whole blood is mixed with coagulation initiators in order to obtain the coagulated blood mass with optimal parameters. This is obtained, inter alia, by selecting particle size of one of the coagulation initiators such as to yield more rapid dissolving within the blood and/or to yield improved suspension of the particles in the blood when it is still in a liquid form. By controlling theses parameters, an optimal coagulated blood mass is obtained that can be used for treatment of the human body, e.g. for treating skin lesions, internal injuries, such as anal fistula, stoma cavity, damaged tendon, and others.